Pharma Mar, S.A. (PHM.MC)
EUR 76.95
(0.59%)
EUR 76.95
(0.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -16.65 Million EUR | 84.46% |
| 2022 | -107.18 Million EUR | -67.43% |
| 2021 | -64.01 Million EUR | -61.88% |
| 2020 | -39.54 Million EUR | -157.75% |
| 2019 | 68.47 Million EUR | -3.09% |
| 2018 | 70.66 Million EUR | -6.92% |
| 2017 | 75.91 Million EUR | -6.51% |
| 2016 | 81.19 Million EUR | -5.55% |
| 2015 | 85.97 Million EUR | 14.76% |
| 2014 | 74.91 Million EUR | 4.33% |
| 2013 | 71.81 Million EUR | -27.03% |
| 2012 | 98.41 Million EUR | -6.6% |
| 2011 | 105.36 Million EUR | -2.08% |
| 2010 | 107.6 Million EUR | 388.9% |
| 2009 | -37.24 Million EUR | 1.48% |
| 2008 | -37.8 Million EUR | -153.81% |
| 2007 | -14.89 Million EUR | -12.68% |
| 2006 | -13.22 Million EUR | -153.76% |
| 2005 | 24.59 Million EUR | -10.98% |
| 2004 | 27.62 Million EUR | 164.27% |
| 2003 | -42.98 Million EUR | 55.34% |
| 2002 | -96.23 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 4.55 Million EUR | 127.32% |
| 2024 Q3 | 1.04 Million EUR | -81.68% |
| 2024 Q2 | 20.06 Million EUR | 340.87% |
| 2023 Q4 | -16.65 Million EUR | 36.9% |
| 2023 Q2 | -32.39 Million EUR | 57.56% |
| 2023 Q1 | -76.32 Million EUR | 28.79% |
| 2023 FY | -16.65 Million EUR | 84.46% |
| 2023 Q3 | -26.39 Million EUR | 18.51% |
| 2022 Q2 | -98.1 Million EUR | 6.17% |
| 2022 Q4 | -107.18 Million EUR | -23.18% |
| 2022 FY | -107.18 Million EUR | -67.43% |
| 2022 Q1 | -104.55 Million EUR | -63.33% |
| 2022 Q3 | -87.01 Million EUR | 11.3% |
| 2021 Q4 | -64.01 Million EUR | 17.57% |
| 2021 FY | -64.01 Million EUR | -61.88% |
| 2021 Q1 | -52.04 Million EUR | -31.61% |
| 2021 Q2 | -72.35 Million EUR | -39.03% |
| 2021 Q3 | -77.66 Million EUR | -7.33% |
| 2020 Q2 | -146.05 Million EUR | -61.64% |
| 2020 Q1 | -90.35 Million EUR | -231.95% |
| 2020 FY | -39.54 Million EUR | -157.75% |
| 2020 Q4 | -39.54 Million EUR | -20.02% |
| 2020 Q3 | -32.94 Million EUR | 77.44% |
| 2019 Q4 | 68.47 Million EUR | 3.88% |
| 2019 Q1 | 88.19 Million EUR | 24.81% |
| 2019 Q2 | 53.81 Million EUR | -38.98% |
| 2019 Q3 | 65.91 Million EUR | 22.5% |
| 2019 FY | 68.47 Million EUR | -3.09% |
| 2018 Q4 | 70.66 Million EUR | -2.59% |
| 2018 FY | 70.66 Million EUR | -6.92% |
| 2018 Q1 | 85.43 Million EUR | 12.54% |
| 2018 Q2 | 95.18 Million EUR | 11.42% |
| 2018 Q3 | 72.53 Million EUR | -23.8% |
| 2017 Q4 | 75.91 Million EUR | -10.96% |
| 2017 FY | 75.91 Million EUR | -6.51% |
| 2017 Q3 | 85.26 Million EUR | 1.37% |
| 2017 Q2 | 84.1 Million EUR | 1.66% |
| 2017 Q1 | 82.73 Million EUR | 1.89% |
| 2016 Q1 | 98.61 Million EUR | 14.7% |
| 2016 Q4 | 81.19 Million EUR | -9.33% |
| 2016 FY | 81.19 Million EUR | -5.55% |
| 2016 Q2 | 99.26 Million EUR | 0.66% |
| 2016 Q3 | 89.55 Million EUR | -9.78% |
| 2015 Q2 | 70.62 Million EUR | -5.19% |
| 2015 Q1 | 74.49 Million EUR | -0.56% |
| 2015 FY | 85.97 Million EUR | 14.76% |
| 2015 Q3 | 70.17 Million EUR | -0.64% |
| 2015 Q4 | 85.97 Million EUR | 22.51% |
| 2014 FY | 74.91 Million EUR | 4.33% |
| 2014 Q4 | 74.91 Million EUR | 4.8% |
| 2014 Q3 | 71.48 Million EUR | -6.02% |
| 2014 Q2 | 76.07 Million EUR | 5.91% |
| 2014 Q1 | 71.82 Million EUR | 0.02% |
| 2013 Q2 | 90.97 Million EUR | 8.6% |
| 2013 FY | 71.81 Million EUR | -27.03% |
| 2013 Q3 | 87.22 Million EUR | -4.12% |
| 2013 Q4 | 71.81 Million EUR | -17.68% |
| 2013 Q1 | 83.77 Million EUR | -14.88% |
| 2012 Q2 | 101.7 Million EUR | -11.38% |
| 2012 Q1 | 114.75 Million EUR | 8.92% |
| 2012 Q3 | 97.13 Million EUR | -4.5% |
| 2012 FY | 98.41 Million EUR | -6.6% |
| 2012 Q4 | 98.41 Million EUR | 1.32% |
| 2011 Q4 | 105.36 Million EUR | 54.67% |
| 2011 FY | 105.36 Million EUR | -2.08% |
| 2011 Q1 | 109.62 Million EUR | 1.88% |
| 2011 Q2 | 117.33 Million EUR | 7.04% |
| 2011 Q3 | 68.12 Million EUR | -41.94% |
| 2010 FY | 107.6 Million EUR | 388.9% |
| 2010 Q1 | 98.62 Million EUR | 364.79% |
| 2010 Q2 | 126.02 Million EUR | 27.79% |
| 2010 Q3 | 126.47 Million EUR | 0.35% |
| 2010 Q4 | 107.6 Million EUR | -14.92% |
| 2009 Q4 | -37.24 Million EUR | 18.99% |
| 2009 FY | -37.24 Million EUR | 1.48% |
| 2009 Q1 | -29.19 Million EUR | 22.78% |
| 2009 Q3 | -45.97 Million EUR | -150.83% |
| 2009 Q2 | 90.45 Million EUR | 409.83% |
| 2008 Q4 | -37.8 Million EUR | 0.0% |
| 2008 FY | -37.8 Million EUR | -153.81% |
| 2007 FY | -14.89 Million EUR | -12.68% |
| 2006 FY | -13.22 Million EUR | -153.76% |
| 2005 FY | 24.59 Million EUR | -10.98% |
| 2004 FY | 27.62 Million EUR | 164.27% |
| 2003 FY | -42.98 Million EUR | 55.34% |
| 2002 FY | -96.23 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Atrys Health, S.A. | 212.17 Million EUR | 107.85% |
| Biotechnologies Assets SA | 6.81 Million EUR | 344.414% |
| Laboratorios Farmaceuticos Rovi, S.A. | 40.1 Million EUR | 141.531% |